Why Orchard Therapeutics Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket
Portfolio Pulse from Lisa Levin
Orchard Therapeutics shares rose by 95.5% in pre-market trading after the company announced a deal to be acquired by Kyowa Kirin Co., Ltd. for a total value of about $477.6 million. Other pre-market gainers include Meiwu Technology, Molekule Group, Femasys, NKGen Biotech, Grom Social Enterprises, Better Choice Company, Momentus, China SXT Pharmaceuticals, and Tenaya Therapeutics. Pre-market losers include Cambium Networks, SIGNA Sports United, MaxCyte, Neoleukin Therapeutics, Safety Shot, Benson Hill, Inspirato, Accolade, and SeaStar Medical Holding Corporation.
October 05, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Orchard Therapeutics shares rose by 95.5% in pre-market trading after the company announced a deal to be acquired by Kyowa Kirin Co., Ltd.
The acquisition deal with Kyowa Kirin Co., Ltd. is a positive development for Orchard Therapeutics and is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
NEGATIVE IMPACT
Cambium Networks shares fell by 27.8% in pre-market trading after the company reported preliminary revenue for the third quarter and suspended its guidance for the full year 2023.
The lower than expected preliminary revenue for the third quarter and the suspension of the full year 2023 guidance are negative developments for Cambium Networks and are likely to have a negative impact on its stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100